All IndicationsOncologyPhase 3Phase 3Phase 3Phase 3Phase 2Phase 2
🎗️
Pancreatic Cancer
7
Companies
7
Drug Programs
4
Phase 3
0
Upcoming PDUFAs
Competitors
APTOF
Aptose Biosciences Inc.
Virulizin®
ALPMY
Astellas Pharma
Setidegrasib
RVMDW
Revolution Medicines, Inc.
daraxonrasib
RVMD
Revolution Medicines, Inc.
Gemcitabine
XBIT
XBiotech Inc.
XB2001 or Placebo
GRTX
Galera Therapeutics, Inc.
GC4419
FVNNU
Forty Seven Inc
RASolute 302
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| APTOF Aptose Biosciences Inc. | Virulizin® | Phase 3 | — | — | — |
| ALPMY Astellas Pharma | Setidegrasib | Phase 3 | — | — | — |
| RVMDW Revolution Medicines, Inc. | daraxonrasib | Phase 3 | — | — | — |
| RVMD Revolution Medicines, Inc. | Gemcitabine | Phase 3 | — | — | — |
| XBIT XBiotech Inc. | XB2001 or Placebo | Phase 2 | — | — | — |
| GRTX Galera Therapeutics, Inc. | GC4419 | Phase 2 | — | — | — |
| FVNNU Forty Seven Inc | RASolute 302 | — | — | — | — |
Development Stage Distribution
Unknown
1
Phase 3
4
Phase 2
2
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.